Position of the Transparency Council – Winrevair (sotatercept)
At its meeting on 2 June 2025, the Transparency Council adopted position No. 66/2025 on the appraisal of drug Winrevair (sotatercept) under drug program B.31. “Treatment of pulmonary arterial hypertension (PAH) (ICD-10 I27, I27.0)”